Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
PrEP Access and Coverage Act This bill requires private health insurance plans to cover prescription drugs that prevent the acquisition of HIV, and any related screenings, diagnostic procedures, or clinical follow-ups, without any cost-sharing obligation for the plan holder. Further, insurance plans must not impose any preauthorization requirement for this coverage. These coverage requirements also apply to public health insurance programs, including, among others, Medicare, Medicaid, and the Children's Health Insurance Program. Additionally, the bill prohibits denying, limiting, or qualifying coverage or increasing premiums for disability insurance, long-term care insurance, or life insurance policies based on a person taking medication for HIV prevention. The bill further requires the Department of Health and Human Services to award grants to states, or directly to eligible local organizations, to provide uninsured individuals access to prescription drugs and related services that prevent HIV. The Centers for Disease Control and Prevention also must develop a public awareness campaign that focuses efforts in communities with a high need for HIV prevention treatment.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2020 · third_quarter · Health Issues
Conversion Therapy Ending Discrimination Against Gay and Bisexual Blood and Tissue Donors Financial Services and General Government Appropriations Funding for HIV/AIDS Education, Prevention, and Research Funding for and Education Regarding Comprehensive Sexual Health Education Health Insurance Privacy Implementation of Section 1557 Nondiscrimination regulations Implementation and Protection of the Patient Protection and Affordable Care Act Interpretation of the Older Americans Act Labor, HHS, and Education Appropriations LGBTQ Data Collection Labor, HHS, and Education Appropriations PrEP Insurance Coverage Planned Parenthood funding Preventing Prohibitions on Gender Transition-Related Care Privacy in Health Insurance Explanation of Benefits Religious Refusals in Healthcare Repeal of Federal Ban on Funding for Syringe Exchange Programs Ryan White CARE Program Reauthorization Unfair Drug Pricing Practices FDA Ban on Blood Donation by MSM COVID-19 Legislative Response Prohibition of Medicaid Funding for Conversion Therapy Act (H.R. 1981) Supporting the goals and ideals of National Youth HIV & AIDS Awareness Day (H.Res. 308) Youth Access to Sexual Health Services Act of 2019 (H.R. 2701; S. 1530) PrEP Access and Coverage Act (H.R. 3815; S. 1926) Healthy Families Act (H.R. 1784; S.840) Real Education for Healthy Youth Act (H.R. 2720; S.1524) Therapeutic Fraud Prevention Act ( H.R. 3570; S. 2008) Eliminating the HHS Discrimination Division Act of 2020 Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748) Families First Coronavirus Response Act (H.R. 6201) The Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (H.R. 6800) To amend title VII of the Public Health Service Act to provide for a loan repayment program for the HIV clinical and dental workforce, and for other purposes. (H.R. 7543) Community Solutions for COVID-19 Act (S. 3877) Health Equity and Accountability Act of 2020 (H.R. 6637) Pursuing Equity in Mental Health Act (H.R. 5469) COVID-19 Health Disparities Action Act of 2020 (H.R. 8203/ S. 4262) COVID-19 in Corrections Data Transparency Act (H.R. 793/S. 4536) Improving Social Determinants of Health Act of 2020 (S. 4440) Science in Blood Donation Act (H.R. 8168) Expressing the sense of the House of Representatives that blood donation policies in the United States should be equitable and based on science. (H.Res. 989)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $150,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Natl AIDS Policy, SENATE, White House Office
2020 · fourth_quarter · Health Issues
Conversion Therapy Ending Discrimination Against Gay and Bisexual Blood and Tissue Donors Financial Services and General Government Appropriations Funding for HIV/AIDS Education, Prevention, and Research Funding for and Education Regarding Comprehensive Sexual Health Education Health Insurance Privacy Implementation of Section 1557 Nondiscrimination regulations Implementation and Protection of the Patient Protection and Affordable Care Act Interpretation of the Older Americans Act Labor, HHS, and Education Appropriations LGBTQ Data Collection Labor, HHS, and Education Appropriations PrEP Insurance Coverage Planned Parenthood funding Preventing Prohibitions on Gender Transition-Related Care Privacy in Health Insurance Explanation of Benefits Religious Refusals in Healthcare Repeal of Federal Ban on Funding for Syringe Exchange Programs Ryan White CARE Program Reauthorization Unfair Drug Pricing Practices FDA Ban on Blood Donation by MSM COVID-19 Legislative Response Prohibition of Medicaid Funding for Conversion Therapy Act (H.R. 1981) Supporting the goals and ideals of National Youth HIV & AIDS Awareness Day (H.Res. 308) Youth Access to Sexual Health Services Act of 2019 (H.R. 2701; S. 1530) PrEP Access and Coverage Act (H.R. 3815; S. 1926) Healthy Families Act (H.R. 1784; S.840) Real Education for Healthy Youth Act (H.R. 2720; S.1524) Therapeutic Fraud Prevention Act ( H.R. 3570; S. 2008) Eliminating the HHS Discrimination Division Act of 2020 Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748) Families First Coronavirus Response Act (H.R. 6201) The Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (H.R. 6800) To amend title VII of the Public Health Service Act to provide for a loan repayment program for the HIV clinical and dental workforce, and for other purposes. (H.R. 7543) Community Solutions for COVID-19 Act (S. 3877) Health Equity and Accountability Act of 2020 (H.R. 6637) Pursuing Equity in Mental Health Act (H.R. 5469) COVID-19 Health Disparities Action Act of 2020 (H.R. 8203/ S. 4262) COVID-19 in Corrections Data Transparency Act (H.R. 793/S. 4536) Improving Social Determinants of Health Act of 2020 (S. 4440) Science in Blood Donation Act (H.R. 8168) Expressing the sense of the House of Representatives that blood donation policies in the United States should be equitable and based on science. (H.Res. 989) World AIDS Day Resolution (H.Res. 1223) COVID Community Care Act (H.R. 8192) The Heroes Act (H.R. 8406)
Client expense: $160,000 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Administration on Aging, Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Natl AIDS Policy, Office of Personnel Management (OPM), Office on Violence Against Women, SENATE, Social Security Administration (SSA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
2020 · third_quarter · Health Issues
Conversion Therapy Ending Discrimination Against Gay and Bisexual Blood and Tissue Donors Financial Services and General Government Appropriations Funding for HIV/AIDS Education, Prevention, and Research Funding for and Education Regarding Comprehensive Sexual Health Education Health Insurance Privacy Implementation of Section 1557 Nondiscrimination regulations Implementation and Protection of the Patient Protection and Affordable Care Act Interpretation of the Older Americans Act Labor, HHS, and Education Appropriations LGBTQ Data Collection Labor, HHS, and Education Appropriations PrEP Insurance Coverage Planned Parenthood funding Preventing Prohibitions on Gender Transition-Related Care Privacy in Health Insurance Explanation of Benefits Religious Refusals in Healthcare Repeal of Federal Ban on Funding for Syringe Exchange Programs Ryan White CARE Program Reauthorization Unfair Drug Pricing Practices FDA Ban on Blood Donation by MSM COVID-19 Legislative Response Prohibition of Medicaid Funding for Conversion Therapy Act (H.R. 1981) Supporting the goals and ideals of National Youth HIV & AIDS Awareness Day (H.Res. 308) Youth Access to Sexual Health Services Act of 2019 (H.R. 2701; S. 1530) PrEP Access and Coverage Act (H.R. 3815; S. 1926) Healthy Families Act (H.R. 1784; S.840) Real Education for Healthy Youth Act (H.R. 2720; S.1524) Therapeutic Fraud Prevention Act ( H.R. 3570; S. 2008) Eliminating the HHS Discrimination Division Act of 2020 Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748) Families First Coronavirus Response Act (H.R. 6201) The Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (H.R. 6800) To amend title VII of the Public Health Service Act to provide for a loan repayment program for the HIV clinical and dental workforce, and for other purposes. (H.R. 7543) Community Solutions for COVID-19 Act (S. 3877) Health Equity and Accountability Act of 2020 (H.R. 6637) Pursuing Equity in Mental Health Act (H.R. 5469) COVID-19 Health Disparities Action Act of 2020 (H.R. 8203/ S. 4262) COVID-19 in Corrections Data Transparency Act (H.R. 793/S. 4536) Improving Social Determinants of Health Act of 2020 (S. 4440) Science in Blood Donation Act (H.R. 8168) Expressing the sense of the House of Representatives that blood donation policies in the United States should be equitable and based on science. (H.Res. 989)
Client expense: $150,000 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Administration on Aging, Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Natl AIDS Policy, Office of Personnel Management (OPM), Office on Violence Against Women, SENATE, Social Security Administration (SSA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
2020 · second_quarter · Health Issues
Conversion Therapy Ending Discrimination Against Gay and Bisexual Blood and Tissue Donors Financial Services and General Government Appropriations Funding for HIV/AIDS Education, Prevention, and Research Funding for and Education Regarding Comprehensive Sexual Health Education Health Insurance Privacy Implementation of Section 1557 Nondiscrimination regulations Implementation and Protection of the Patient Protection and Affordable Care Act Interpretation of the Older Americans Act Labor, HHS, and Education Appropriations LGBTQ Data Collection Labor, HHS, and Education Appropriations PrEP Insurance Coverage Planned Parenthood funding Preventing Prohibitions on Gender Transition-Related Care Privacy in Health Insurance Explanation of Benefits Religious Refusals in Healthcare Repeal of Federal Ban on Funding for Syringe Exchange Programs Ryan White CARE Program Reauthorization Unfair Drug Pricing Practices FDA Ban on Blood Donation by MSM COVID-19 Legislative Response Prohibition of Medicaid Funding for Conversion Therapy Act (H.R. 1981) Supporting the goals and ideals of National Youth HIV & AIDS Awareness Day (H.Res. 308) Youth Access to Sexual Health Services Act of 2019 (H.R. 2701; S. 1530) PrEP Access and Coverage Act (H.R. 3815; S. 1926) Healthy Families Act (H.R. 1784; S.840) Real Education for Healthy Youth Act (H.R. 2720; S.1524) Therapeutic Fraud Prevention Act ( H.R. 3570; S. 2008) Eliminating the HHS Discrimination Division Act of 2020 Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748) Families First Coronavirus Response Act (H.R. 6201) The Heroes Act (H.R. 6800) To amend title VII of the Public Health Service Act to provide for a loan repayment program for the HIV clinical and dental workforce, and for other purposes. (H.R. 7543) Community Solutions for COVID-19 Act (S. 3877) Health Equity and Accountability Act of 2020 (H.R. 6637) The Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748)
Client expense: $140,000 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Administration on Aging, Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Natl AIDS Policy, Office of Personnel Management (OPM), Office on Violence Against Women, SENATE, Social Security Administration (SSA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
2020 · first_quarter · Health Issues
Conversion Therapy Ending Discrimination Against Gay and Bisexual Blood and Tissue Donors Financial Services and General Government Appropriations Funding for HIV/AIDS Education, Prevention, and Research Funding for and Education Regarding Comprehensive Sexual Health Education Health Insurance Privacy Implementation of Section 1557 Nondiscrimination regulations Implementation and Protection of the Patient Protection and Affordable Care Act Interpretation of the Older Americans Act Labor, HHS, and Education Appropriations LGBTQ Data Collection Labor, HHS, and Education Appropriations PrEP Insurance Coverage Planned Parenthood funding Preventing Prohibitions on Gender Transition-Related Care Privacy in Health Insurance Explanation of Benefits Religious Refusals in Healthcare Repeal of Federal Ban on Funding for Syringe Exchange Programs Ryan White CARE Program Reauthorization Unfair Drug Pricing Practices FDA Ban on Blood Donation by MSM COVID-19 Legislative Response Prohibition of Medicaid Funding for Conversion Therapy Act (H.R. 1981) Supporting the goals and ideals of National Youth HIV & AIDS Awareness Day (H.Res. 308) Youth Access to Sexual Health Services Act of 2019 (H.R. 2701; S. 1530) PrEP Access and Coverage Act (H.R. 3815; S. 1926) Healthy Families Act (H.R. 1784; S.840) Real Education for Healthy Youth Act (H.R. 2720; S.1524) Therapeutic Fraud Prevention Act ( H.R. 3570; S. 2008) Eliminating the HHS Discrimination Division Act of 2020 Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748) Families First Coronavirus Response Act (H.R. 6201)
Client expense: $170,000 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Administration on Aging, Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Natl AIDS Policy, Office of Personnel Management (OPM), Office on Violence Against Women, SENATE, Social Security Administration (SSA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
2019 · fourth_quarter · Health Issues
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act
Client expense: $1,300,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2019 · fourth_quarter · Health Issues
Conversion Therapy Ending Discrimination Against Gay and Bisexual Blood and Tissue Donors Financial Services and General Government Appropriations Funding for HIV/AIDS Education, Prevention, and Research Funding for and Education Regarding Comprehensive Sexual Health Education Health Insurance Privacy HIV Organ Policy Equity (HOPE) Act Implementation Implementation of Section 1557 Nondiscrimination regulations Implementation and Protection of the Patient Protection and Affordable Care Act Interpretation of the Older Americans Act Labor, HHS, and Education Appropriations LGBTQ Data Collection Planned Parenthood funding Preventing Prohibitions on Gender Transition-Related Care Privacy in Health Insurance Explanation of Benefits Religious Refusals in Healthcare Repeal of Federal Ban on Funding for Syringe Exchange Programs Ryan White CARE Program Reauthorization Unfair Drug Pricing Practices Prohibition of Medicaid Funding for Conversion Therapy Act (H.R. 1981) Supporting the goals and ideals of National Youth HIV & AIDS Awareness Day (H.Res. 308) Therapeutic Fraud Prevention Act (H.R. 3570; S. 2008) Youth Access to Sexual Health Services Act of 2019 (H.R. 2701; S. 1530) PrEP Access and Coverage Act (H.R. 3815; S. 1926)
Client expense: $200,000 · Firm income: Not reported
2019 · third_quarter · Health Issues
Conversion Therapy Ending Discrimination Against Gay and Bisexual Blood and Tissue Donors Financial Services and General Government Appropriations Funding for HIV/AIDS Education, Prevention, and Research Funding for and Education Regarding Comprehensive Sexual Health Education Health Insurance Privacy HIV Organ Policy Equity (HOPE) Act Implementation Implementation of Section 1557 Nondiscrimination regulations Implementation and Protection of the Patient Protection and Affordable Care Act Interpretation of the Older Americans Act Labor, HHS, and Education Appropriations LGBTQ Data Collection Planned Parenthood funding Preventing Prohibitions on Gender Transition-Related Care Privacy in Health Insurance Explanation of Benefits Religious Refusals in Healthcare Repeal of Federal Ban on Funding for Syringe Exchange Programs Ryan White CARE Program Reauthorization Unfair Drug Pricing Practices Prohibition of Medicaid Funding for Conversion Therapy Act (H.R. 1981) Supporting the goals and ideals of National Youth HIV & AIDS Awareness Day (H.Res. 308) Therapeutic Fraud Prevention Act (H.R. 3570; S. 2008) Youth Access to Sexual Health Services Act of 2019 (H.R. 2701; S. 1530) PrEP Access and Coverage Act (H.R. 3815; S. 1926)
Client expense: $130,000 · Firm income: Not reported
2019 · third_quarter · Health Issues
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. S.1416 - Affordable Prescriptions for Patients Act of 2019 S.1895 - Lower Health Care Costs Act H.R.3 - Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act
Client expense: $1,480,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2019 · second_quarter · Medicare/Medicaid
H.R. 107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid drug rebates H.R. 275: Medicare Prescription Drug Price Negotiation Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 366: Insulin Access for All Act of 2019 - Provisions related to insulin cost-sharing H.R. 448: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation H.R. 937: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification H.R. 1034: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates H.R. 1035: Prescription Drug Price Transparency Act - Provisions related to drug pricing transparency and pharmacy benefit managers H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing H.R. 1346: Medicare Buy-In and Health Care Stabilization Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 1384: Medicare for All Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights H.R. 1781: Payment Commission Data Act - Provisions related to prescription drug pricing transparency and reporting H.R. 1788: Medicare Part B Fairness Act - Provisions related to Part B enrollment H.R. 1839: Medicaid Services Investment and Accountability Act - Provisions related to Medicaid drug rebates and drug classification H.R. 2000: Medicare-X Choice Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 2452: Medicare for America Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 2463: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation H.R. 2757: Creating Lower cost Alternative for Your prescription drugs Act - Provisions related to Part D and patient cost-sharing H.R. 3029: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans H.R. 3107: Improving Seniors' Timely Access to Care Act of 2019 - Provisions related to Medicare Advantage insurance plans H.R. 3276: Fair AMP Act - Provisions related to Medicaid drug rebates S. 62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 - Provisions related to Part D and drug pricing negotiation S. 99: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation S. 205: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification S. 377: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCap) Act of 2019 - Provisions related to Part D and patient cost-sharing S. 470: Medicare at 50 Act - Provisions related to Part D and drug pricing negotiation S. 476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers S. 551: Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 - Provisions related to prescription drug vial sizes and rebates S. 640: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates S. 691: Medicare Extra Rx Higher Eligibility Limits in Part D Act of 2019 - Provisions related to Part D and patient out-of-pocket costs S. 801: Payment Commission Data Act - Provisions related to prescription drug pricing transparency and reporting S. 1129: Medicare for All Act of 2019 - Provisions related to Part D and drug pricing negotiation S. 1261: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation S. 1785: Fair AMP Act - Provisions related to Medicaid drug rebates S. 1801: Affordable Medications Act - Provisions relate to Part D drug pricing negotiation, importation, IP issues and pricing transparency S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling - Provisions related to prescription drug labeling S. 1926: PrEP Access and Coverage Act - PrEP insurance coverage requirement and grant program for uninsured S. __: Patient Affordability Value and Efficiency Act - Value-based arrangements Medicare Access and Childrens Health Insurance Program (CHIP) reauthorization policy issues Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Part B reform including MedPAC recommendations and other policy issues and local coverage decisions Drug cost and pricing policy issues Transparency policy issues Alternative payment models policy issues Value-based purchasing arrangements policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid rebates and waiver policy issues Prescription drug abuse policy issues ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Proposed Rule; Medicare and Medicaid Programs; Regulation To Require Drug Pricing Transparency (CMS-4187-P) Proposed Rule; Contract Year (CY) 2020 Medicare Advantage and Part D Drug Pricing (CMS-4180-P) Request for Information: Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Anti-Kickback Statute and Beneficiary Inducements CMP; 83 Fed. Reg. 43607 (Aug. 27, 2018) Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08)
2019 · second_quarter · Medicare/Medicaid
H.R. 107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid drug rebates H.R. 275: Medicare Prescription Drug Price Negotiation Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 366: Insulin Access for All Act of 2019 - Provisions related to insulin cost-sharing H.R. 448: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation H.R. 937: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification H.R. 1034: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates H.R. 1035: Prescription Drug Price Transparency Act - Provisions related to drug pricing transparency and pharmacy benefit managers H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing H.R. 1346: Medicare Buy-In and Health Care Stabilization Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 1384: Medicare for All Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights H.R. 1781: Payment Commission Data Act - Provisions related to prescription drug pricing transparency and reporting H.R. 1788: Medicare Part B Fairness Act - Provisions related to Part B enrollment H.R. 1839: Medicaid Services Investment and Accountability Act - Provisions related to Medicaid drug rebates and drug classification H.R. 2000: Medicare-X Choice Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 2452: Medicare for America Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 2463: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation H.R. 2757: Creating Lower cost Alternative for Your prescription drugs Act - Provisions related to Part D and patient cost-sharing H.R. 3029: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans H.R. 3107: Improving Seniors' Timely Access to Care Act of 2019 - Provisions related to Medicare Advantage insurance plans H.R. 3276: Fair AMP Act - Provisions related to Medicaid drug rebates S. 62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 - Provisions related to Part D and drug pricing negotiation S. 99: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation S. 205: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification S. 377: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCap) Act of 2019 - Provisions related to Part D and patient cost-sharing S. 470: Medicare at 50 Act - Provisions related to Part D and drug pricing negotiation S. 476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers S. 551: Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 - Provisions related to prescription drug vial sizes and rebates S. 640: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates S. 691: Medicare Extra Rx Higher Eligibility Limits in Part D Act of 2019 - Provisions related to Part D and patient out-of-pocket costs S. 801: Payment Commission Data Act - Provisions related to prescription drug pricing transparency and reporting S. 1129: Medicare for All Act of 2019 - Provisions related to Part D and drug pricing negotiation S. 1261: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation S. 1785: Fair AMP Act - Provisions related to Medicaid drug rebates S. 1801: Affordable Medications Act - Provisions relate to Part D drug pricing negotiation, importation, IP issues and pricing transparency S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling - Provisions related to prescription drug labeling S. 1926: PrEP Access and Coverage Act - PrEP insurance coverage requirement and grant program for uninsured S. __: Patient Affordability Value and Efficiency Act - Value-based arrangements Medicare Access and Childrens Health Insurance Program (CHIP) reauthorization policy issues Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Part B reform including MedPAC recommendations and other policy issues and local coverage decisions Drug cost and pricing policy issues Transparency policy issues Alternative payment models policy issues Value-based purchasing arrangements policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid rebates and waiver policy issues Prescription drug abuse policy issues ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Proposed Rule; Medicare and Medicaid Programs; Regulation To Require Drug Pricing Transparency (CMS-4187-P) Proposed Rule; Contract Year (CY) 2020 Medicare Advantage and Part D Drug Pricing (CMS-4180-P) Request for Information: Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Anti-Kickback Statute and Beneficiary Inducements CMP; 83 Fed. Reg. 43607 (Aug. 27, 2018) Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08)
2019 · second_quarter · Medicare/Medicaid
H.R. 107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid drug rebates H.R. 275: Medicare Prescription Drug Price Negotiation Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 366: Insulin Access for All Act of 2019 - Provisions related to insulin cost-sharing H.R. 448: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation H.R. 937: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification H.R. 1034: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates H.R. 1035: Prescription Drug Price Transparency Act - Provisions related to drug pricing transparency and pharmacy benefit managers H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing H.R. 1346: Medicare Buy-In and Health Care Stabilization Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 1384: Medicare for All Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights H.R. 1781: Payment Commission Data Act - Provisions related to prescription drug pricing transparency and reporting H.R. 1788: Medicare Part B Fairness Act - Provisions related to Part B enrollment H.R. 1839: Medicaid Services Investment and Accountability Act - Provisions related to Medicaid drug rebates and drug classification H.R. 2000: Medicare-X Choice Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 2452: Medicare for America Act of 2019 - Provisions related to Part D and drug pricing negotiation H.R. 2463: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation H.R. 2757: Creating Lower cost Alternative for Your prescription drugs Act - Provisions related to Part D and patient cost-sharing H.R. 3029: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans H.R. 3107: Improving Seniors' Timely Access to Care Act of 2019 - Provisions related to Medicare Advantage insurance plans H.R. 3276: Fair AMP Act - Provisions related to Medicaid drug rebates S. 62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 - Provisions related to Part D and drug pricing negotiation S. 99: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation S. 205: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification S. 377: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCap) Act of 2019 - Provisions related to Part D and patient cost-sharing S. 470: Medicare at 50 Act - Provisions related to Part D and drug pricing negotiation S. 476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers S. 551: Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 - Provisions related to prescription drug vial sizes and rebates S. 640: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates S. 691: Medicare Extra Rx Higher Eligibility Limits in Part D Act of 2019 - Provisions related to Part D and patient out-of-pocket costs S. 801: Payment Commission Data Act - Provisions related to prescription drug pricing transparency and reporting S. 1129: Medicare for All Act of 2019 - Provisions related to Part D and drug pricing negotiation S. 1261: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation S. 1785: Fair AMP Act - Provisions related to Medicaid drug rebates S. 1801: Affordable Medications Act - Provisions relate to Part D drug pricing negotiation, importation, IP issues and pricing transparency S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling - Provisions related to prescription drug labeling S. 1926: PrEP Access and Coverage Act - PrEP insurance coverage requirement and grant program for uninsured S. __: Patient Affordability Value and Efficiency Act - Value-based arrangements Medicare Access and Childrens Health Insurance Program (CHIP) reauthorization policy issues Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Part B reform including MedPAC recommendations and other policy issues and local coverage decisions Drug cost and pricing policy issues Transparency policy issues Alternative payment models policy issues Value-based purchasing arrangements policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid rebates and waiver policy issues Prescription drug abuse policy issues ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Proposed Rule; Medicare and Medicaid Programs; Regulation To Require Drug Pricing Transparency (CMS-4187-P) Proposed Rule; Contract Year (CY) 2020 Medicare Advantage and Part D Drug Pricing (CMS-4180-P) Request for Information: Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Anti-Kickback Statute and Beneficiary Inducements CMP; 83 Fed. Reg. 43607 (Aug. 27, 2018) Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08)
Government targets: Administration for Children & Families (ACF), Administration on Aging, Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Natl AIDS Policy, Office of Personnel Management (OPM), Office on Violence Against Women, SENATE, Social Security Administration (SSA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
Government targets: Administration for Children & Families (ACF), Administration on Aging, Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Natl AIDS Policy, Office of Personnel Management (OPM), Office on Violence Against Women, SENATE, Social Security Administration (SSA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
Client expense: $6,310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $870,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $6,220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)